a sustained-release formulation of a potent gonadotropin-releasing hormone ( gnrh ) agonist , zoladex ( d-ser ( but ) ,6 aza gly10-gnrh ; ici 118,630 ; goserelin ) , was administered subcutaneously ( 3.6 mg/depot ) to male rats once every 28 days for 2-24 wk to determine the extent to which pituitary-testis function could be suppressed and whether suppression was maintained throughout the period of treatment .
C0023610
gnrh
C0120107
goserelin